



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

WITHDRAWN: Dupilumab: A review of potential in the treatment of Chronic rhinosinusitis with nasal polyps (CRSwNP)

T.Y. Sree Sudha¹, T. Pugazhenthana^{2,*}, K.S.B.S. Krishna Sasanka³, T.Y. Sri Hari⁴, A.R. Vijayakumar⁵

¹ *Department of Pharmacology, AIIMS, Raipur, Chhattisgarh, India*

² *Department of Pharmacology, AIIMS, Raipur, Chhattisgarh, India*

³ *Department of Otolaryngology, Head and Neck Surgery, AIIMS, Raipur, Chhattisgarh, India*

⁴ *Department of Emergency Medicine, KIMS, Secundrabad, Andhra, India*

⁵ *Department of Pharmacology, JIPMER, Karaikal, India*

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause.

The full Elsevier Policy on Article Withdrawal can be found at <https://www.elsevier.com/about/our-business/policies/article-withdrawal>

* Corresponding author.

E-mail address: drpugal23@gmail.com (T. Pugazhenthana).